Cardio-Cerebrovascular Protective Effects of Valsartan in High-Risk Hypertensive Patients With Coronary Artery Disease (from the Kyoto Heart Study)

被引:14
|
作者
Shiraishi, Jun [1 ]
Sawada, Takahisa [2 ]
Koide, Masahiro [2 ]
Yamada, Hiroyuki [2 ]
Matsubara, Hiroaki [2 ]
机构
[1] Kyoto First Red Cross Hosp, Dept Cardiol, Kyoto, Japan
[2] Kyoto Prefectural Univ, Sch Med, Dept Cardiovasc Med, Kyoto 606, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2012年 / 109卷 / 09期
关键词
CASE-J TRIAL; CARDIOVASCULAR EVENTS; SUBANALYSIS; MORBIDITY; MORTALITY; RAMIPRIL;
D O I
10.1016/j.amjcard.2011.12.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective was to examine whether previous coronary artery disease (CAD) influences the add-on effects of the angiotensin II receptor blocker (ARB) valsartan on cardio-cerebrovascular morbidity and mortality in high-risk hypertensive patients who participated in the Kyoto Heart Study. The primary end point was the same as in the main study: a composite of new-onset and/or worsening of cardiovascular and cerebrovascular events. Median follow-up was 3.27 years. According to the presence of previous CAD at baseline, the study population was divided into 2 groups (with CAD, n = 707; without CAD, n = 2,324) in which primary end-point events occurred more frequently in patients with CAD than in patients without CAD (15.1% vs 5.6%, hazard ratio [HR] 2.68, 95% confidence interval [CI] 2.11 to 3.42). Add-on valsartan significantly decreased the occurrence of the primary end-point events in patients with CAD (11.3% vs 19.0%, HR 0.59, 95% CI 0.41 to 0.85) and without CAD (3.7% vs 7.6%, HR 0.49, 95% CI 0.34 to 0.70) compared to non-ARB treatment. In the presence of previous CAD, patients with valsartan add-on treatment had a significantly lower prevalence of angina pectoris and stroke than those with non-ARB treatment, whereas the valsartan add-on effects on angina and stroke were not significant in the absence of CAD. Changes in blood pressure during the follow-up period did not differ significantly between study subgroups. In conclusion, in the presence or absence of previous CAD, valsartan add-on treatment prevented more cardio-cerebrovascular events than conventional non-ARB treatment in high-risk hypertensive patients. In addition, valsartan add-on treatment conferred not only an antianginal effect but also stroke prevention exclusively in hypertensive patients with CAD compared to those without CAD. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;109:1308-1314)
引用
收藏
页码:1308 / 1314
页数:7
相关论文
共 50 条
  • [41] Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study
    Deidda, Martino
    Noto, Antonio
    Dessalvi, Christian Cadeddu
    Andreini, Daniele
    Andreotti, Felicita
    Ferrannini, Eleuterio
    Latini, Roberto
    Maggioni, Aldo P.
    Magnoni, Marco
    Mercuro, Giuseppe
    METABOLITES, 2022, 12 (02)
  • [42] CEREBROVASCULAR DISEASE Identifying high-risk patients from carotid plaque composition
    Spence, J. David
    NATURE REVIEWS CARDIOLOGY, 2010, 7 (08) : 426 - 428
  • [43] Protective Effects of Angiotensin-Converting Enzyme Inhibitors in High-Risk African American Men With Coronary Heart Disease
    Papademetriou, Vasilios
    Kaoutzanis, Christodoulos
    Dumas, Michael
    Pittaras, Andreas
    Faselis, Charles
    Kokkinos, Peter
    Fletcher, Ross D.
    JOURNAL OF CLINICAL HYPERTENSION, 2009, 11 (11): : 621 - 626
  • [44] Hybrid Coronary Revascularization for the Treatment of Left Main Coronary Artery Disease in High-Risk Patients
    Fedakar, Ali
    Tasar, Mehmet
    Rabus, Murat Bulen
    Alsalehi, Saleh
    Toker, Mehmet Erdem
    Balkanay, Mehmet
    HEART SURGERY FORUM, 2012, 15 (01): : E51 - E55
  • [45] Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: Insights from the Heart and Soul Study
    Grenon, S. Marlene
    Vittinghoff, Eric
    Owens, Christopher D.
    Conte, Michael S.
    Whooley, Mary
    Cohen, Beth E.
    VASCULAR MEDICINE, 2013, 18 (04) : 176 - 184
  • [46] Amlodipine Reduces Predicted Risk of Coronary Heart Disease in High-risk Patients with Hypertension in Spain (The CORONARIA Study)
    Zamorano, J.
    Rodriguez Padial, L.
    Cosin, J.
    Hernandiz, A.
    Gutierrez-Chico, J. L.
    Perez De Isla, L.
    Aristegui, R.
    Masramon, X.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2008, 36 (06) : 1399 - 1417
  • [47] High-Risk Percutaneous Coronary Intervention in Patients With Stable Ischemic Heart Disease
    Weintraub, William S.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2019, 20 (04) : 269 - 270
  • [48] Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients
    Malacco, E
    Piazza, S
    Scandiani, L
    Zoppi, A
    ADVANCES IN THERAPY, 2004, 21 (03) : 149 - 161
  • [49] Effects of valsartan/ hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients
    Ettore Malacco
    Simona Piazza
    Luciana Scandiani
    Annalisa Zoppi
    Advances in Therapy, 2004, 21 : 149 - 161
  • [50] Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
    Kjeldsen, Sverre E.
    Julius, Stevo
    Mancia, Giuseppe
    McInnes, Gordon T.
    Hua, Tsushung
    Weber, Michael A.
    Coca, Antonio
    Ekman, Steffan
    Girerd, Xavier
    Jamerson, Kenneth
    Larochelle, Pierre
    MacDonald, Thomas M.
    Schmieder, Roland E.
    Schork, M. Anthony
    Stolt, Pelle
    Viskoper, Reuven
    Widimsky, Jiri
    Zanchetti, Alberto
    JOURNAL OF HYPERTENSION, 2006, 24 (07) : 1405 - 1412